HEPA
Price
$0.47
Change
+$0.02 (+4.44%)
Updated
Jan 17 closing price
Capitalization
3.26M
TNFA
Price
$1.16
Change
-$0.03 (-2.52%)
Updated
Jan 17 closing price
Capitalization
3.2M
Ad is loading...

HEPA vs TNFA

Header iconHEPA vs TNFA Comparison
Open Charts HEPA vs TNFABanner chart's image
Hepion Pharmaceuticals
Price$0.47
Change+$0.02 (+4.44%)
Volume$74.7K
Capitalization3.26M
TNF Pharmaceuticals
Price$1.16
Change-$0.03 (-2.52%)
Volume$141.19K
Capitalization3.2M
HEPA vs TNFA Comparison Chart
Loading...
HEPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TNFA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HEPA vs. TNFA commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HEPA is a Hold and TNFA is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (HEPA: $0.47 vs. TNFA: $1.16)
Brand notoriety: HEPA and TNFA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HEPA: 120% vs. TNFA: 63%
Market capitalization -- HEPA: $3.26M vs. TNFA: $3.2M
HEPA [@Biotechnology] is valued at $3.26M. TNFA’s [@Biotechnology] market capitalization is $3.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HEPA’s FA Score shows that 1 FA rating(s) are green whileTNFA’s FA Score has 1 green FA rating(s).

  • HEPA’s FA Score: 1 green, 4 red.
  • TNFA’s FA Score: 1 green, 4 red.
According to our system of comparison, TNFA is a better buy in the long-term than HEPA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HEPA’s TA Score shows that 5 TA indicator(s) are bullish while TNFA’s TA Score has 2 bullish TA indicator(s).

  • HEPA’s TA Score: 5 bullish, 4 bearish.
  • TNFA’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, HEPA is a better buy in the short-term than TNFA.

Price Growth

HEPA (@Biotechnology) experienced а -8.04% price change this week, while TNFA (@Biotechnology) price change was -8.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

HEPA is expected to report earnings on Aug 30, 2023.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HEPA($3.26M) and TNFA($3.2M) have the same market capitalization . TNFA YTD gains are higher at: 0.870 vs. HEPA (-0.234). TNFA has higher annual earnings (EBITDA): -11.38M vs. HEPA (-29.39M). TNFA has more cash in the bank: 10.6M vs. HEPA (1.5M). TNFA has less debt than HEPA: TNFA (18.3K) vs HEPA (2.22M). HEPA (0) and TNFA (0) have equivalent revenues.
HEPATNFAHEPA / TNFA
Capitalization3.26M3.2M102%
EBITDA-29.39M-11.38M258%
Gain YTD-0.2340.870-27%
P/E RatioN/AN/A-
Revenue00-
Total Cash1.5M10.6M14%
Total Debt2.22M18.3K12,153%
FUNDAMENTALS RATINGS
HEPA vs TNFA: Fundamental Ratings
HEPA
TNFA
OUTLOOK RATING
1..100
9134
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
8
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
9436
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TNFA's Valuation (8) in the null industry is in the same range as HEPA (33). This means that TNFA’s stock grew similarly to HEPA’s over the last 12 months.

TNFA's Profit vs Risk Rating (100) in the null industry is in the same range as HEPA (100). This means that TNFA’s stock grew similarly to HEPA’s over the last 12 months.

TNFA's SMR Rating (99) in the null industry is in the same range as HEPA (100). This means that TNFA’s stock grew similarly to HEPA’s over the last 12 months.

TNFA's Price Growth Rating (36) in the null industry is somewhat better than the same rating for HEPA (94). This means that TNFA’s stock grew somewhat faster than HEPA’s over the last 12 months.

TNFA's P/E Growth Rating (100) in the null industry is in the same range as HEPA (100). This means that TNFA’s stock grew similarly to HEPA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HEPATNFA
RSI
ODDS (%)
Bullish Trend 11 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 11 days ago
87%
Momentum
ODDS (%)
Bullish Trend 11 days ago
72%
Bearish Trend 11 days ago
90%
MACD
ODDS (%)
Bullish Trend 11 days ago
90%
Bearish Trend 11 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
75%
Bullish Trend 11 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
85%
Advances
ODDS (%)
Bullish Trend 13 days ago
77%
Bullish Trend 11 days ago
82%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 20 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 11 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
HEPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TNFA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RBAIX26.680.14
+0.53%
T. Rowe Price Balanced I
WFTCX4.950.02
+0.41%
Allspring Innovation Fund - Class C
NINCX20.460.07
+0.34%
Neuberger Berman Intrinsic Value C
TSCIX13.680.03
+0.22%
AMG TimesSquare Small Cap Growth Z
VIDMX8.470.01
+0.12%
Virtus KAR Developing Markets I

TNFA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TNFA has been loosely correlated with COGT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if TNFA jumps, then COGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TNFA
1D Price
Change %
TNFA100%
-2.52%
COGT - TNFA
39%
Loosely correlated
-1.23%
PHAT - TNFA
39%
Loosely correlated
N/A
TVGN - TNFA
35%
Loosely correlated
+5.79%
HEPA - TNFA
33%
Poorly correlated
+4.22%
LRMR - TNFA
32%
Poorly correlated
+2.77%
More